The debt/equity ratio shows how much a company has borrowed for every dollar its shareholders have put in. It is long-term debt, both the part due within a year and the rest, divided by shareholder equity, shown as a multiple with both amounts in the table. A higher ratio means the company relies more on borrowed money than on shareholder capital. Because equity shrinks through buybacks or losses, the ratio can rise even when debt is unchanged, and it has no meaning when equity is negative. Quarterly points use quarter-end balances; annual points use fiscal-year-end balances.
Indivior Pharmaceuticals, Inc. debt/equity ratio for the quarter ending 2026-06-30 was -2.34, a change of -1.07 year-over-year.
Indivior Pharmaceuticals, Inc. debt/equity ratio for the quarter ending 2026-03-31 was -3.38, a change of -2.22 year-over-year.
Indivior Pharmaceuticals, Inc. debt/equity ratio for the quarter ending 2025-12-31 was -3.26, a change of -2.27 year-over-year.
Indivior Pharmaceuticals, Inc. debt/equity ratio for the quarter ending 2025-09-30 was -1.56.
Indivior Pharmaceuticals, Inc. debt/equity ratio for fiscal 2025 was -3.26, a change of -2.27 from fiscal 2024.
Indivior Pharmaceuticals, Inc. debt/equity ratio for fiscal 2024 was -0.99, a change of 0.32 from fiscal 2023.
Indivior Pharmaceuticals, Inc. debt/equity ratio for fiscal 2023 was -1.3.